GHRP-2, also called pralmorelin, is a synthetic growth hormone secretagogue that acts as a ghrelin-receptor agonist and prompts the pituitary to release growth hormone. The published record groups its reported effects into short-term reactions, hormonal spillover onto cortisol and prolactin, slower metabolic costs, and the sourcing hazards that follow a compound sold as a research chemical rather than an approved medicine. GHRP-2 is not approved for general human use in most jurisdictions, is banned in competitive sport, and carries limited long-term human safety data.
GHRP-2 is an unapproved research compound whose documented risks span appetite and fluid effects, cortisol and prolactin elevation, reduced insulin sensitivity from sustained growth hormone and IGF-1, and unregulated-sourcing hazards, all against limited long-term human safety data.
The short-term effects reported most consistently track the peptide's mechanism and the act of injecting it rather than any exotic reaction. The appetite surge is described as near-universal and can begin within twenty to thirty minutes, because GHRP-2 activates the same ghrelin receptor that signals hunger. Reported intensity scales with dose, so larger or more frequent injections are said to amplify hunger and fluid effects rather than introduce new ones.
The most frequently reported short-term effects of GHRP-2 are a pronounced appetite surge beginning within 20 to 30 minutes, transient flushing and tingling, mild water retention, and injection-site reactions, with intensity reported to rise alongside dose.
GHRP-2 is not perfectly selective for the growth hormone axis. When it activates receptors in the pituitary and hypothalamus, it can also prompt release of adrenocorticotropic hormone, which drives cortisol production, and it can modestly stimulate prolactin. The record describes this spillover as mild at typical low doses and more noticeable as doses climb, and it places GHRP-2 toward the higher end among secretagogues for both hormones, which is why it is often characterized as stronger but less clean.
| Concern | Cortisol elevation | Prolactin elevation |
|---|---|---|
| Body composition | Increased abdominal fat storage | Reduced libido |
| Systemic | Blood-sugar and blood-pressure disturbance | Breast tissue sensitivity in men |
| Other | Mood disruption, suppressed immunity | Menstrual irregularity in women |
GHRP-2 stimulates adrenocorticotropic hormone and prolactin alongside growth hormone and sits toward the higher end among secretagogues, so sustained use is associated with cortisol-driven abdominal fat and blood-sugar and blood-pressure disturbance plus prolactin-driven libido, breast-tissue, and menstrual effects.
The metabolic risks are among the most important and the least visible, because they build quietly instead of announcing themselves. Growth hormone is counter-regulatory to insulin, so as its levels rise cells become less responsive to insulin and the liver releases more glucose. The literature frames this as a direction of effect and a theoretical IGF-1 concern rather than a demonstrated long-term outcome in peptide users, which is why caution is emphasized despite limited direct evidence.
Because growth hormone is counter-regulatory to insulin, repeated GHRP-2 dosing can raise fasting blood glucose and reduce insulin sensitivity toward a prediabetic state, while chronically elevated downstream IGF-1 carries a theoretical concern about promoting existing abnormal-cell growth.
The intense hunger is not incidental; it is a direct pharmacological result of how GHRP-2 works. The peptide binds the growth hormone secretagogue receptor, the same receptor the hunger hormone ghrelin uses, sending a strong signal to eat that can override normal satiety within half an hour of dosing. The fluid retention comes from a separate arm of the same cascade, and the two together explain how unmanaged use can undercut the body-composition goals that motivated it.
GHRP-2 sharply increases hunger because it binds the same growth hormone secretagogue receptor that ghrelin uses, while fluid retention arises from growth-hormone-driven sodium and water reabsorption in the kidneys, two separate arms of a single cascade.
The published record identifies several groups at meaningfully higher risk and frames some as clear contraindications rather than cautious footnotes. Active or prior cancer sits at the top of that list, because GHRP-2 raises IGF-1, a growth factor that can theoretically support the proliferation of abnormal cells. Since the compound is unapproved and sold as a research chemical, none of these groups have a prescriber screening them for these contraindications before use.
GHRP-2 is contraindicated for people with a cancer history because it raises IGF-1, and it is generally advised against for those with diabetes or metabolic disorders, pregnancy or breastfeeding, pituitary or other endocrine disease, cardiovascular conditions, and minors.
A large share of the real-world risk with GHRP-2 comes not from the molecule but from where and how it is obtained. Because it is sold predominantly as a research chemical rather than a regulated medicine, there is no consistent oversight of what is actually in the vial. Mislabeled concentration is documented as a particular hazard, since a dose calculated from an incorrect stated strength can be far off in either direction without the user knowing.
Because GHRP-2 is sold as an unregulated research chemical, vials can contain the wrong peptide, mislabeled concentrations, synthesis byproducts, or endotoxins, and independent testing of a single batch reduces but does not remove the sterility and consistency uncertainty.
The honest answer is that the long-term risks are largely uncharacterized, and that uncertainty is itself a risk worth naming. Because GHRP-2 has never gone through the multi-year controlled trials approved medicines require, there is no robust body of evidence describing what happens to people who use it steadily for years. In practical terms, sustained use amounts to participating in an experiment whose long-term endpoints have not been measured.
GHRP-2's long-term and lifetime-exposure risks are largely uncharacterized because it has never undergone multi-year controlled trials, leaving the theoretical concern of IGF-1-driven tumor promotion, possible receptor desensitization, and unknown effects on endogenous growth hormone regulation unresolved.
GHRP-2 is not approved as a therapeutic medicine for general human use in most jurisdictions, and where it is encountered it is typically sold and labeled as a research chemical not intended for human consumption. Its close relationship to pralmorelin gives it a history of investigational and diagnostic use in evaluating growth hormone secretion, a narrow context far removed from open therapeutic approval. The practical consequence is that use proceeds entirely outside clinical oversight, which is where grey-market economics turn into a safety issue.
GHRP-2 is not approved for general human use in most jurisdictions, is sold as a research chemical, and is banned in competitive sport, so its use proceeds without prescriber screening, pharmacist verification, or medical monitoring.
Educational use only. This article describes what the published scientific and clinical literature reports about GHRP-2. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
